Overview

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Status:
Enrolling by invitation
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, extended study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of SHR-1819 injection in adult subjects with moderate to severe atopic dermatitis who have previously participated in the SHR-1819 injection study for atopic dermatitis (defined as the main study, referred to as the main study hereinafter).
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.